We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300124:SZSEShenzhen Inovance Technology Co., Ltd Class A Analysis

Data as of 2026-03-15 - not real-time

CN¥72.79

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Shenzhen Inovance trades at CNY 72.79, just below its 20‑day SMA (CNY 72.93) and well under its 50‑day SMA (CNY 75.48), indicating a modest short‑term pullback despite a bullish MACD histogram (+0.09) and rising volume. Revenue is expanding at a robust 21% YoY and margins remain healthy (gross 27.5%, operating 13.1%), but the latest Morningstar note flags elevated input costs that could compress profit margins in 2025. Valuation metrics are stretched – the PE of 37.9 sits above the industry average of 29.1 and the DCF‑derived fair value of CNY 31.95 is less than half the current price, suggesting the stock is significantly overvalued at present.
The balance sheet shows ample cash (CNY 11.9 bn) and a modest debt‑to‑equity of 13.2%, supporting dividend sustainability (0.56% yield, 21% payout). However, the 30‑day volatility of ~28% and a max drawdown of 23.5% highlight price swings, while a low beta (~0.25) points to limited market‑wide correlation. Overall, the company’s growth story in automation and new‑energy vehicles is compelling, but the current premium pricing and cost‑headwinds advise caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near short‑term support and below SMA20
  • Elevated input costs pressure margins
  • Technical indicators neutral with modest bullish bias

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong 21% revenue growth and expanding automation market
  • Valuation premium remains high relative to DCF and peers
  • Improving cash position offsets moderate leverage

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Secular demand for industrial automation and NEV components
  • Sustainable dividend with low payout ratio
  • Low beta and solid balance sheet support long‑run resilience

Key Metrics & Analysis

Financial Health

Revenue Growth21.00%
Profit Margin11.97%
P/E Ratio37.9
ROE16.66%
ROA5.25%
Debt/Equity13.23
P/B Ratio5.7
Op. Cash FlowCN¥7.3B
Free Cash FlowCN¥2.5B
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI48.5
SupportCN¥67.62
ResistanceCN¥78.59
MA 20CN¥72.93
MA 50CN¥75.48
MA 200CN¥72.05
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueCN¥31.95
Target PriceCN¥87.92
Upside/Downside20.79%
GradeOvervalued
TypeGrowth
Dividend Yield0.56%

Risk Assessment

Beta0.25
Volatility27.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.